Voriconazol y tamsulosina: interacción farmacológica clínicamente relevante

Parramón-Teixidó, Carlos Javier; Pau-Parra, Alba; Burgos, Joaquin; Campany, David.
Enferm. infecc. microbiol. clín. (Ed. impr.) ; 39(7): 361-363, Ago-Sep. 2021. graf
Artículo en Español | IBECS (España) | ID: ibc-209587

Documentos relacionados

  1. Continuous-Flow Synthesis of (R)-Tamsulosin Utilizing Sequential Heterogeneous Catalysis.
  2. Voriconazole and tamsulosin: A clinically relevant drug-drug interaction.
  3. Formulation and Evaluation of Eudragit® RL Polymeric Double Layer Films for Prolonged-Release Transdermal Delivery of Tamsulosin Hydrochloride.
  4. Impact of early vs. delayed initiation of dutasteride/tamsulosin combination therapy on the risk of acute urinary retention or BPH-related surgery in LUTS/BPH patients with moderate-to-severe symptoms at risk of disease progression.
  5. Smart UV spectrophotometric methods based on simple mathematical filtration and classical methods for the simultaneous determination of tamsulosin and solifenacin: A comparative study of efficacy and spectral resolution.
  6. Can we decide the optimal initial treatment for male lower urinary tract symptoms patients with overactive bladder by the most bothersome symptom? A randomized, prospective, open-label study.
  7. Therapeutic Effects of Tamsulosin in Nightmare Disorder: A Randomized, Double Blind, Placebo-Controlled, Cross-Over, Pilot Study.
  8. Re: Effect of Tamsulosin on Passage of Symptomatic Ureteral Stones: A Randomized Clinical Trial.
  9. Re: Efficacy of Tamsulosin, Oxybutynin, and Their Combination in the Control of Double-J Stent-Related Lower Urinary Tract Symptoms.
  10. Tamsulosin 0.8 mg daily dose in management of BPH patients with failed tamsulosin 0.4 mg monotherapy and unfit for surgical intervention.